Epiretinal Membrane Progression Following Cataract Surgery
- PMID: 41020169
- PMCID: PMC12463874
- DOI: 10.1177/24741264251367126
Epiretinal Membrane Progression Following Cataract Surgery
Abstract
Purpose: To investigate the progression of epiretinal membrane (ERM) following cataract surgery using optical coherence tomography (OCT)-based biomarkers. Methods: A retrospective review was conducted from January 2012 to February 2022, assessing eyes with preexisting idiopathic ERM that underwent uncomplicated cataract surgery. An established ERM grading scale was used, and OCT features, along with visual outcomes, were evaluated. Results: The study followed 67 eyes for an average of 47.8 months after cataract surgery. Initially, 83.6% of eyes had stage 1 ERM, 13.4% had stage 2, and 3% had stage 3. Nonsignificant ERM progression occurred 59 weeks postoperatively. Among stage 1 eyes, 16.1% progressed to stage 2; 11.1% of stage 2 eyes progressed to stage 3; and 50% of stage 3 eyes progressed to stage 4. Additionally, 10.4% developed or experienced worsened macular edema following cataract surgery, and 6% underwent vitrectomy. In eyes managed without vitrectomy, visual acuity (VA) improved 1 month after cataract surgery (P = .018) and remained stable over a 4-year period. Conclusions: Eyes with mild-stage ERM that demonstrate improved VA after cataract surgery tend to maintain these improvements over a 4-year period and do not typically progress.
Keywords: cataract; epiretinal membrane; optical coherence tomography; phacoemulsification.
© The Author(s) 2025.
Conflict of interest statement
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The following disclosures have been reported: J.H.: consultant for IvericBio and Gyroscope Therapeutics; grant support from IvericBio, Aldeyra Therapeutics, and Genentech/Roche; O.G.: Consultant for Alcon; C.R.: 4DMT, Adverum, Alcon, Allergan, Annexon, Apellis, Clearside, Cognition, Eyepoint, Genentech, Iveric, Janssen, Kodiak, Merck, NGM, Novartis, Ocular Therapeutics, Ocugen, Ocuphire, Ocuterra, Ray, Regeneron, RegenXBio, Stealth, Thea, Zeiss; A.C.H.: Scientific Advisor for Alcon Surgical.
References
-
- Morillon C, Le Goff M, Gattoussi S, et al. Incidence, progression, and risk factors of epiretinal membranes in the elderly. Retina. 2021;41(3):495-504. - PubMed
-
- Pike D, Mandelcorn ED, Sheidow T, Whelan JH. Inner-limiting-membrane peeling in epiretinal membrane surgery: an evolving surgical trend. Can J Ophthalmol. 2020;55(2):e72-e74. - PubMed
-
- Govetto A, Lalane RA, III, Sarraf D, Figueroa MS, Hubschman JP. Insights into epiretinal membranes: presence of ectopic inner foveal layers and a new optical coherence tomography staging scheme. Am J Ophthalmol. 2017;175:99-113. - PubMed
LinkOut - more resources
Full Text Sources